慢性骨髄性白血病に対するBcr-Abl阻害剤とALDH阻害剤併用による抗腫瘍効果

DOI Web Site

書誌事項

タイトル別名
  • The Effect of Combined Bcr-Abl Inhibitor and ALDH Inhibitor on Chronic Myelogenous Leukemia

抄録

<p>【Introduction】Chronic myelogenous leukemia (CML) has become a disease with five-year-survival rate of more than 90% according to appearance of Bcr-Abl inhibitor. Stopping treatment with Bcr-Abl inhibitors leads to relapse in many patients. This is due to the fact that Bcr-Abl inhibitors are not effective against cancer stem cells, and suggests that a different drug is necessary to eradicate cancer stem cells. ALDH is overexpressed in cancer stem cells and promotes their survival. We have shown in past studies that Bcr-Abl inhibitors do not inhibit ALDH expression. In this study, we examine the effect of ALDH inhibitors on CML.</p><p>【Methods】We examined the effects of an ALDH inhibitor using K562 cells, which are CML cell line. We verified the effect of an ALDH inhibitor against CML using a WST-8 assay. We then measured ALDH protein expression using flow cytometry.</p><p>【Results】ALDH inhibitors reduced cell survival in a concentration-dependent manner, and when combined with a Bcr-Abl inhibitor, cell viability was synergistically decreased. ALDH protein expression was decreased in cells treated with ALDH inhibitor alone or Bcr-Abl inhibitor alone according to flow cytometry. In cells treated with ALDH inhibitor and Bcr-Abl inhibitor, ALDH protein expression was more strongly repressed.</p><p>【Conclusion】The results of this study suggest that ALDH inhibitor use might be effective in CML treatment.</p>

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ